GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OHEL:NANOFH) » Definitions » Other Operating Expense

Nanoform Finland (OHEL:NANOFH) Other Operating Expense : €22.19 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland Other Operating Expense?

Nanoform Finland's Other Operating Expense for the three months ended in Mar. 2024 was €6.03 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €22.19 Mil.

Nanoform Finland's quarterly Other Operating Expense increased from Sep. 2023 (€4.78 Mil) to Dec. 2023 (€5.66 Mil) and increased from Dec. 2023 (€5.66 Mil) to Mar. 2024 (€6.03 Mil).

Nanoform Finland's annual Other Operating Expense increased from Dec. 2021 (€18.83 Mil) to Dec. 2022 (€21.37 Mil) but then declined from Dec. 2022 (€21.37 Mil) to Dec. 2023 (€21.30 Mil).


Nanoform Finland Other Operating Expense Historical Data

The historical data trend for Nanoform Finland's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland Other Operating Expense Chart

Nanoform Finland Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial 5.59 15.22 18.83 21.37 21.30

Nanoform Finland Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.14 5.72 4.78 5.66 6.03

Nanoform Finland Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanoform Finland Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoform Finland (OHEL:NANOFH) Business Description

Traded in Other Exchanges
Address
Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OHEL:NANOFH) Headlines

No Headlines